Taysha Gene Therapies (NASDAQ:TSHA) Trading 7% Higher – What’s Next?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shares were up 7% during trading on Wednesday . The company traded as high as $4.31 and last traded at $4.3450. Approximately 406,910 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 3,840,116 shares. The stock had previously closed at $4.06.

Analysts Set New Price Targets

Several brokerages have recently weighed in on TSHA. JMP Securities set a $8.00 target price on Taysha Gene Therapies in a research report on Wednesday, November 5th. UBS Group set a $11.00 price objective on shares of Taysha Gene Therapies in a report on Thursday. Chardan Capital restated a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a research report on Wednesday, November 5th. Robert W. Baird increased their target price on shares of Taysha Gene Therapies from $7.00 to $12.00 and gave the company an “outperform” rating in a research report on Thursday, October 2nd. Finally, Needham & Company LLC reiterated a “buy” rating and set a $10.00 price target on shares of Taysha Gene Therapies in a research note on Friday, October 17th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Taysha Gene Therapies has a consensus rating of “Moderate Buy” and an average price target of $10.42.

Taysha Gene Therapies Price Performance

The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48. The company has a 50 day moving average price of $4.49 and a 200 day moving average price of $3.35. The firm has a market cap of $1.38 billion, a PE ratio of -15.30 and a beta of 1.06.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. Sell-side analysts expect that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Sukumar Nagendran sold 260,047 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $4.51, for a total value of $1,172,811.97. Following the completion of the sale, the insider owned 1,006,439 shares in the company, valued at $4,539,039.89. This trade represents a 20.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 570,172 shares of company stock valued at $2,341,906 in the last three months. 3.78% of the stock is owned by company insiders.

Institutional Trading of Taysha Gene Therapies

A number of institutional investors have recently modified their holdings of the business. Xponance Inc. raised its holdings in Taysha Gene Therapies by 29.1% during the third quarter. Xponance Inc. now owns 16,575 shares of the company’s stock worth $54,000 after purchasing an additional 3,738 shares during the last quarter. Principal Financial Group Inc. raised its stake in shares of Taysha Gene Therapies by 33.6% during the 3rd quarter. Principal Financial Group Inc. now owns 16,251 shares of the company’s stock worth $53,000 after buying an additional 4,091 shares during the last quarter. ST Germain D J Co. Inc. boosted its position in shares of Taysha Gene Therapies by 81.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after buying an additional 4,333 shares in the last quarter. Granahan Investment Management LLC grew its stake in Taysha Gene Therapies by 0.3% in the 1st quarter. Granahan Investment Management LLC now owns 1,640,793 shares of the company’s stock valued at $2,281,000 after acquiring an additional 4,412 shares during the last quarter. Finally, Legal & General Group Plc grew its stake in Taysha Gene Therapies by 25.8% in the 3rd quarter. Legal & General Group Plc now owns 23,149 shares of the company’s stock valued at $76,000 after acquiring an additional 4,754 shares during the last quarter. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.